# Absci Corporation (ABSI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.82, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Absci Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 969.7×**. Each dollar of revenue is priced at 969.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 6.1×**. The shares trade at 6.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.2%** (5-yr avg -27.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -60.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -57.5%**. Return on all capital, debt included, is -57.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -56.0%**. Each dollar of assets produces -56.0% of profit.

## Growth
- **Revenue growth (1 yr): -38.2%** (3-yr -21.3%/yr, 5-yr -10.1%/yr). Revenue fell 38.2% over the last year, against -10.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 10.6%**. Earnings per share rose 10.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 6.57** (quick 6.57). Current assets cover the next year's liabilities 6.57 times.
- **Altman Z-score: 33.93**. A Z-score of 33.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Absci Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Absci Corporation; the consensus is strong_buy, with an average price target of $13.89 (+57% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 267.5%** (YTD 152.7%, 3-mo 37.8%). The shares are up 267.5% over twelve months including dividends.
- **From 52-week high: -26.8%** (293.7% above the low). Trading 27% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 3.35** (volatility 106%). Beta of 3.35 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABSI · Page: https://foliofundamentals.com/stocks/absi

Not investment advice.